Ahead of the London Marathon this weekend (21 April), we chatted to Team CF runner Tom to hear all about his reasons for running, inspiring others, and what a life unlimited means to him.
The aim of the study is to assess the safety and effectiveness of ETD001, a new therapy for people with CF to improve mucociliary clearance and lung function. If you can’t take CFTR modulator treatments, or you are not currently taking CFTR modulator treatments, you may be eligible to take part in this study. This is a new approach to nebulised medication that aids mucus clearance, to potentially improve lung function. It works in a different way to current nebulised medication. We need to conduct trials to see how effective this different mode of action is, to ensure we are...
Part A is now closed and Part B is open to recruitment.
Trials Tracker ID
TT014193
Age range
18 years or older
Length of participation
Part A: maximum of 56 days. Part B: maximum of 140 days
The aim of this study is to measure the long-term safety, tolerability, and effectiveness of a combination of medicines (VX-121/TEZ/D-IVA) in people with CF. The treatment is made up of three medications: VX-121, tezacaftor and deutivacaftor. Deutivacaftor is a slightly modified version of ivacaftor that is potentially more stable in the body. This means deutivacaftor can be taken once a day instead of twice a day. Patients will receive a single, daily dose of VX-121/TEZ/D-IVA in tablet form. Participants will be asked to visit the CF clinic around 12 times over a period of 96 weeks, with an additional follow-up...
The UK Health Security Agency (UKHSA) have announced that from today, 15 April, those most at risk from developing severe COVID-19 will be able to book their vaccine booster.
Researchers at the University of Liverpool have made some key findings in their attempt to find a way to treat infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa), including serious infections in the lungs of people with cystic fibrosis. These infections can be resistant to antibiotic treatments.
With the countdown to the London Marathon well and truly on, we spoke to our Team CF runner Nell, 22, to find out how her training is going, her motivations for taking part and why she’s determined to not let cystic fibrosis (CF) hold her back.
The ENHANCE study aims to better understand various aspects of the lives and health of children from birth to adulthood with cystic fibrosis (CF). Though people with CF have more treatment options now, there is still a lot we need to understand about CF in babies and children. This study will monitor how CF complications develop in young children and how different groups of children with CF develop features of the condition. The research will also compare infants (0-1 years) of a similar age with and without CF. The study will be made up of three groups of participants. Group...
Emily’s Entourage - a US-based non-profit organisation focused on research and drug development for rare cystic fibrosis mutations - latest survey findings show that those not benefitting from modulators continue to live with a substantial treatment burden, and this is impacting their quality of life.
